SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ambrx Biopharma, Inc. Buyout

newsfile ·  Jan 16 13:45

Wilmington, Delaware--(Newsfile Corp. - January 16, 2024) - Rigrodsky Law, P.A. is investigating Ambrx Biopharma, Inc. ("Ambrx") (NASDAQ: AMAM) regarding possible breaches of fiduciary duties and other violations of law related to Ambrx's agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, Ambrx shareholders will receive $28.00 per share in cash.

To learn more about this investigation and your rights, visit: .

To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky Law, P.A.
Seth D. Rigrodsky, Esq.
Gina M. Serra, Esq.
Call or Text: (302) 295-5310

To view the source version of this press release, please visit

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment